Skip to main content
Have a personal or library account? Click to login
Effect of Vasoactive Intestinal Peptide (VIP) on Cytokine Levels and Haemostatic and Biochemical Parameters in A Rat Endotoxaemic Model Cover

Effect of Vasoactive Intestinal Peptide (VIP) on Cytokine Levels and Haemostatic and Biochemical Parameters in A Rat Endotoxaemic Model

By:  and    
Open Access
|Jan 2013

References

  1. 1. Al-Dughaym A.M.: Some endotoxin-induced clinical and biochemical changes in plasma of camels (). Vet Res Commun 2004,, 711-718.
  2. 2. Allam G.: Vasoactive intestinal peptide inhibits liver pathology in acute murineand modulates IL-10, IL-12 and TNF-1 production. Immunobiology 2007,, 603-612.
  3. 3. Asakura H., Asamura R., Ontachi Y., Hayashi T., Yamazaki M., Morishita E., Miyamoto K.I., Nakao S.: Selective inducible nitric oxide synthase inhibition attenuates organ dysfunction and elevated endothelin levels in LPS-induced DIC model rats. J Thromb Haemost 2005,, 1050-1055.
  4. 4. Col R., Keskin E., Atalay B.: Effect of pentoxifylline on endotoxin-induced haemostatic disturbances in rabbits. Acta Vet Hung 2005,, 325-335.
  5. 5. Delgado M., Martinez C., Pozo D., Calvo J.R., Leceta J., Ganea D., Gomariz R.P.: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-a and IL-6. J Immunol 1999,, 1200-1205.
  6. 6. Delgado M., Pozo D., Martinez C., Leceta J., Calvo J.R., Ganea D., Gomariz R.P.: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-a production by macrophages,andstudies. J Immunol 1999,, 2358-2367.
  7. 7. Dhuley J.N., Naik S.R.: Effect of rhinax on bacterial lipopolysaccharide induced endotoxemia in rats. Indian J Exp Biol 1998,, 315-317.
  8. 8. Fernández-Martínez E., Morales-Ríos M.S., Pérez- Alvarez V., Muriel P.: Immunomodulatory effects of thalidomide analogs on LPS-induced plasma and hepatic cytokines in the rat. Biochem Pharmacol 2004,, 1321-1329.
  9. 9. Fourrier F., Chopin C., Huart J.J., Runge I., Caron C., Goudemand J.: Double-blind placebo-controlled trial of antithrombin III concentrate in septic shock with disseminated intravascular coagulation. Chest 1993,, 882-892.
  10. 10. Fraunberg P., Schaefer S., Werdan K., Walli A.K., Seidel D.: Reduction of circulating cholesterol and apoliloprotein levels during sepsis. Clin Chem Lab Med 1999,, 357-362.
  11. 11. Gaviria J.M., Dale D.C., Root R.K.: Neutrophils: function and role in sepsis syndrome. Sepsis 1998,, 107-117.
  12. 12. Gonzalez-Rey E., Delgado M.: Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007,, 241-251.
  13. 13. Grimm M.C., Newman R., Hassim Z., Cuan N., Connor S.J., Le Y., Wang J.M., Oppenheim J.J., Lloyd A.R.: Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammationby transdeactivating chemokine receptors. J Immunol 2003,, 4990-4994.
  14. 14. Hayashi T., Kishiwada M., Fujii K., Yuasa H., Nishioka J., Ido M., Gabazza E.C., Suzuki K.: Lipopolysaccharide-induced decreased protein S expression in liver cells is mediated by MEK/ERK signaling and NFjB activation: involvement of membrane-bound CD14 and toll-like receptor-4. J Thromb Haemost 2006,, 1763-1773.
  15. 15. Hopper K., Bateman S.: An updated view of hemostasis: mechanisms of hemostatic dysfuntion associated with sepsis. J Vet Emerg Crit Care 2005,, 83-91.
  16. 16. Iba T., Nakarai .E, Takayama T., Nakajima K., Sasaoka T., Ohno Y.: Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model. Crit Care 2009,, R203.
  17. 17. Izutani W., Fujita M., Nishizawa K., Koga J.: Urinary protein C inhibitor as a therapeutic agent to disseminated intravascular coagulation (DIC): A comparison with low molecular weight heparin in rats with lipopolysaccharide-induced DIC. Biol Pharm Bull 2000,, 1046-1050.
  18. 18. Lauw F.N., Pajkrt D., Hack C.E., Kurimoto M., van Deventer S.J.H., van der Poll T.: Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 2000,, 2783-2789.
  19. 19. Levi M., de Jonge E., van der Poll T.: Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001,, 90-94.
  20. 20. Mathiak G., Grass G., Herzmann T., Luebke T., Zetina C.C., Boehm S.A., Bohlen H., Neville L.F., Hoelscher A.H.: Caspase-1-inhibitor ac-YVAD-cmk reduces LPSlethality in rats without affecting haematology or cytokine responses. Br J Pharmacol 2000,, 383-386.
  21. 21. Møller S., Laigaard F., Olgaard K., Hemmingsen C.: Effect of 1,25-dihydroxy-vitamin D3 in experimental sepsis. Int J Med Sci 2007,, 190-195.
  22. 22. Pozo D., Guerrero J.M., Calvo J.R.: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit LPS-stimulated MIP-1α production and mRNA expression. Cytokine 2002,, 35-42.
  23. 23. Said S.I.: Vasoactive intestinal peptide and nitric oxide: divergent roles in relation to tissue injury. Ann NY Acad Sci 1996,, 379-387.
  24. 24. Saito K., Yamatani K., Manaka H., Takahashi K., Tominaga M., Sasaki H.: Role of Ca2+ on vasoactive intestinal peptide-induced glucose and adenosine 3',5'- monophosphate production in the isolated perfused rat liver. Endocrinology 1992,, 2267-2273.
  25. 25. Tuncel N., Tore F., Sahinturk V., Ak D, Tuncel M.: Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: a potential therapeutic strategy in controlling septic shock. Peptides 2000,, 81-89.
  26. 26. van Devender S.J.H., Buller H.R., ten Cate J.W., Aareden L.A., Hack C.E., Sturk A.: Experimental endotoxemia in humans; analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990,, 2520-2526.
  27. 27. van Veen S.Q., Cheung C.W., Meijers J.C.M., van Gulik T.M., Boermeester M.A.: Anticoagulant and antiinflammatory effects after peritoneal lavage with antithrombin in experimental polymicrobial peritonitis. J Thromb Haemost 2006,, 2343-2351.
  28. 28. van Westerloo D.J., Giebelen I.A.J., Meijers J.C.M., Daalhuisen J., de Vos A.F., Levi M., van der Poll T.: Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats. J Thromb Haemost 2006,, 1997-2002.
  29. 29. Yamazaki M., Aoshima K., Mizutani T., Ontachi Y., Saito M., Morishita E., Asakura H., Matsuda T., Triplett D.A.: Prednisolone inhibits endotoxin-induced disseminated intravascular coagulation and improves mortality in rats: İmportance of inflammatory cytokine suppression Blood Coag Fibrinol 1999,, 321-330.
  30. 30. Yang H., Li Q.W., Han Z.S., Hu J.H., Li W.Y., Liu Z.B.: Recombinant human antithrombin expressed in the milk of non-transgenic goats exhibits high efficiency on rat DIC model. J Thromb Thrombolysis 2009,, 449-457.
  31. 31. Yazar E., Col R., Konyalıoglu S., Birdane Y.O., Elmas M., Bas A.L.: Effects of vitamın E and prednisolone on biochemical and haematological parameters in endotoxaemic New Zealand white rabbits. Bull Vet Inst Pulawy, 2004,, 105-108.
  32. 32. Yun-Choi H.S., Pyo M.K., Chang K.C., Lee D.H.: The effects of higenamine on LPS-induced experimental disseminated intravascular coagulation (DIC) in rats. Planta Med 2002,, 326-329.
DOI: https://doi.org/10.2478/v10213-012-0012-6 | Journal eISSN: 2450-8608 (formerly 2300-3235)
Language: English
Page range: 63 - 67
Published on: Jan 17, 2013
Published by: National Veterinary Research Institute in Pulawy
In partnership with: Paradigm Publishing Services

© 2013 Ramazan Col, Zafer Durgun, published by National Veterinary Research Institute in Pulawy
This work is licensed under the Creative Commons License.